dalteparin

Summary

Summary: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Top Publications

  1. Kovacs M, Kahn S, Rodger M, Anderson D, Andreou R, Mangel J, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost. 2007;5:1650-3 pubmed
    ..effectiveness of a management strategy for central venous catheter-related DVT in cancer patients consisting of dalteparin and warfarin without the need for line removal...
  2. Dahl O, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997;77:26-31 pubmed
    ..All patients received initial thromboprophylaxis with dalteparin, dextran and graded elastic stockings. On day 7, patients were randomised to receive dalteparin (Fragmin) 5000 i...
  3. Leizorovicz A, Cohen A, Turpie A, Olsson C, Vaitkus P, Goldhaber S. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-9 pubmed
    ..double-blind, placebo-controlled trial using clinically important outcomes to assess the efficacy and safety of dalteparin in the prevention of venous thromboembolism in such patients...
  4. Nasstrom B, Stegmayr B, Olivecrona G, Olivecrona T. Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. J Lab Clin Med. 2003;142:90-9 pubmed
    ..This study indicates that LMW heparin compared with conventional heparin causes as much or more depletion of LPL and subsequent impairment of TG clearing. ..
  5. Matziolis G, Perka C, Disch A, Zippel H. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int. 2003;73:370-9 pubmed
    ..Unfractionated heparin (UFH), dalteparin, enoxaparin and fondaparinux were added to osteoblast cultures in the therapeutic range and two decimal powers ..
  6. Rommers M, Van der Lely N, Egberts T, van den Bemt P. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care. 2006;10:R93 pubmed
    ..It is unknown whether the presence of subcutaneous oedema impairs the absorption of dalteparin, a low molecular weight heparin, when it is given by subcutaneous administration for venous thromboembolism ..
  7. Robins H, O Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B, et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol. 2008;62:227-33 pubmed
    ..b>Dalteparin (5,000 U sub-Q daily) was given with and after conventional radiotherapy to newly diagnosed GBM patients...
  8. Marmur J, Poludasu S, Feit A, Battala V, Cavusoglu E. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention. J Invasive Cardiol. 2008;20:323-7 pubmed
    ..time (ACT) has been reported to be sensitive to the anticoagulant activity of the low-molecular weight heparin dalteparin following intravenous (IV) administration...
  9. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res. 1999;96:275-82 pubmed
    ..Low molecular weight heparins, such as dalteparin, also may be suitable, but randomised trials have not been performed...

More Information

Publications62

  1. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283-92 pubmed publisher
    ..three APC patients were randomised to receive either gemcitabine 1000 mg/m(2) or the same with weight-adjusted dalteparin (WAD) for 12 weeks. Primary end-point was the reduction of all-type VTE during the study period...
  2. Kucher N, Leizorovicz A, Vaitkus P, Cohen A, Turpie A, Olsson C, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165:341-5 pubmed
    We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients...
  3. Kereiakes D, Kleiman N, Fry E, Mwawasi G, Lengerich R, Maresh K, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J. 2001;141:348-52 pubmed
    Despite proved efficacy for either dalteparin or platelet glycoprotein IIb/IIIa blockade in improving clinical outcomes of patients with non-ST-segment elevation acute coronary syndromes, algorithms guiding concomitant therapy with these ..
  4. Komericki P, Grims R, Kranke B, Aberer W. Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol. 2007;57:718-21 pubmed
    ..We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis...
  5. Malm K, Dahlback B, Arnljots B. Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg. 2003;111:1659-66 pubmed
    ..authors compared the antithrombotic and antihemostatic effects of heparin and the low-molecular-weight heparin dalteparin in a rat model of arterial thrombosis...
  6. Dunn C, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs. 2000;60:203-37 pubmed
    b>Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of 5000...
  7. Kim W, Jeong M, Hwang S, Kim K, Hong Y, Ahn Y, et al. Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients. Int Heart J. 2006;47:821-31 pubmed
    ..study was to determine the clinical outcomes of abciximab combined with the low molecular weight heparin (LMWH), dalteparin, in high-risk percutaneous coronary intervention (PCI) patients with acute myocardial infarction (AMI)...
  8. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med. 2008;168:1805-12 pubmed publisher
    ..To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency...
  9. Jessen L, Wiinberg B, Jensen A, Kjelgaard Hansen M, Jensen K, Pedersen L, et al. In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting ti. Vet Clin Pathol. 2008;37:363-72 pubmed publisher
    ..Low-molecular-weight heparin (LMWH) is being used increasingly in veterinary medicine for both treatment and prophylaxis of thromboembolic disease, but no predictable patient-side method exists to monitor its effect...
  10. Natarajan M, Velianou J, Turpie A, Mehta S, Raco D, Goodhart D, et al. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J. 2006;151:175 pubmed
    Direct comparison of low-molecular-weight heparin, dalteparin, with unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) is limited...
  11. Chiou Tan F, Garza H, Chan K, Parsons K, Donovan W, Robertson C, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. Am J Phys Med Rehabil. 2003;82:678-85 pubmed
    To determine differences between dalteparin and enoxaparin in patients with spinal cord injury. This prospective, randomized, open-label study was performed as a multiple hospital trial in a large urban setting...
  12. Wells P, Anderson D, Rodger M, Forgie M, Florack P, Touchie D, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2005;165:733-8 pubmed
    ..We compared 2 LMWH products, tinzaparin and dalteparin sodium, for the treatment of acute DVT and PE in a randomized, controlled clinical trial of consecutive ..
  13. Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics. 2006;24:593-607 pubmed
    ..thromboembolism]), which evaluated secondary prophylaxis of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52% compared with oral anticoagulation therapy (p = 0.002)...
  14. Kontny F, Dale J, Abildgaard U, Pedersen T. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30:962-9 pubmed
    The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)...
  15. Kovacs M, Levine M, Keeney M, Mackinnon K, Lee A. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thromb Haemost. 2005;93:1185-8 pubmed
    ..6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin (200 IU per kilogram) subcutaneously daily...
  16. Kalani M, Silveira A, Blomback M, Apelqvist J, Eliasson B, Eriksson J, et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res. 2007;120:653-61 pubmed
    ..We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin. In the present study we investigated the effects of dalteparin on skin microcirculation and haemostatic ..
  17. Simoneau M, Vachon A, Picard F. Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg. 2010;20:487-91 pubmed publisher
    ..The objective of this study was to describe the postoperative effects of LMWH dalteparin on anti-factor Xa (AFXa) level in morbidly obese patients undergoing bariatric surgery...
  18. Lund E, Olsen M, Lipson K, McMahon G, Howlett A, Kristjansen P. Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia. 2003;5:155-60 pubmed
    The effect of combining SU5416 with fractionated radiotherapy or with low molecular weight (LMW) heparin (dalteparin) was studied in U87 human glioblastoma xenografts in nude mice...
  19. Lassen M, Borris L, Anderson B, Jensen H, Skejø Bro H, Andersen G, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998;89:281-7 pubmed
    ..Following seven days on a standard length regimen of dalteparin (5000 antifactor Xa units subcutaneously once daily starting 12 h before surgery), patients were randomized to ..
  20. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol. 1999;33:627-33 pubmed
    This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 ..
  21. Montalescot G, Bal dit Sollier C, Chibedi D, Collet J, Soulat T, Dalby M, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003;91:925-30 pubmed
    The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over unfractionated heparin (UFH) in patients with unstable angina pectoris (UAP) or non-ST-segment elevation ..
  22. MacDonald R, Amidei C, Baron J, Weir B, Brown F, Erickson R, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol. 2003;59:363-72; discussion 372-4 pubmed
    Unfractionated heparin and the low molecular weight heparin, dalteparin, are used for prophylaxis against venous thromboembolism in patients undergoing craniotomy...
  23. Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53 pubmed
    ..thrombosis, pulmonary embolism, or both were randomly assigned to receive low-molecular-weight heparin (dalteparin) at a dose of 200 IU per kilogram of body weight subcutaneously once daily for five to seven days and a coumarin ..
  24. Kakkar A, Levine M, Kadziola Z, Lemoine N, Low V, Patel H, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-8 pubmed
    ..advanced malignancy (N = 385) were randomly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year...
  25. Nassiri A, Hakemi M, Soulati M, Marashian M, Rahbar K, Azizi F. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease. Iran J Kidney Dis. 2009;3:162-7 pubmed
    ..This study was planned in order to evaluate the antioxidant effects of heparin and dalteparin (low-molecular weight heparin). Twenty-two patients underwent 3 hemodialysis sessions with 48-hour intervals...
  26. Eriksson B, Arfwidsson A, Frison L, Eriksson U, Bylock A, Kälebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibitio. Thromb Haemost. 2002;87:231-7 pubmed
    ..Another 33 patients received dalteparin 5000 IU s.c. once daily, started the evening before surgery, for 8-11 days...
  27. Pineo G, Hull R. Dalteparin sodium. Expert Opin Pharmacother. 2001;2:1325-37 pubmed
    b>Dalteparin sodium (Fragmin, Pharmacia Corporation) is a low molecular weight heparin (LMWH) with a mean molecular weight of approximately 5000 Da...
  28. Tam N, Pac Soo C, Pretorius P. Epidural haematoma after a combined spinal-epidural anaesthetic in a patient treated with clopidogrel and dalteparin. Br J Anaesth. 2006;96:262-5 pubmed
    ..She had been taking clopidogrel and had received perioperative dalteparin for thromboprophylaxis...
  29. Wilson S, Wilbur K, Burton E, Anderson D. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42-8 pubmed
    ..Patients with serum creatinine levels < 150 micromol/l receiving the LMWH, dalteparin 200 anti-Xa IU/kg based on actual body weight subcutaneously once daily for the treatment of deep vein ..
  30. Raaz U, Buerke M, Busshardt M, Maegdefessel L, Plehn A, Hauroeder B, et al. Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. J Thromb Thrombolysis. 2010;29:265-70 pubmed publisher
    ..is a critical intervention in preventing catheter thrombus formation and (ii) other LMWH such as certoparin or dalteparin are as effective as enoxaparin...
  31. Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005;146:333-43 pubmed
    ..xenografts were subcutaneously injected with either unfractionated heparin (UFH; 200 units kg(-1) day(-1)), dalteparin (75 units kg(-1) day(-1)) or danaparoid (50 units kg(-1) day(-1))...
  32. Wong N, Buckman R, Clemons M, Verma S, Dent S, Trudeau M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial . J Clin Oncol. 2010;28:723-30 pubmed publisher
    ..We designed a phase I/II study to evaluate the safety and activity of adding dalteparin and prednisone to metronomic cyclophosphamide and methotrexate in women with measurable metastatic breast cancer ..
  33. Rabbat C, Cook D, Crowther M, McDonald E, Clarke F, Meade M, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005;20:357-63 pubmed
    ..objectives of this study were to assess, among medical-surgical patients in the intensive care unit receiving dalteparin 5,000 IU daily for thromboprophylaxis, (1) the relationship between renal dysfunction and LMWH bioaccumulation ..
  34. Harada N, Okajima K, Uchiba M. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. Crit Care Med. 2006;34:1883-91 pubmed
    To examine whether dalteparin, a low molecular weight heparin, prevents hepatic damage by inhibiting leukocyte activation, we analyzed its effect on ischemia/reperfusion (I/R) injury of rat liver in which activated leukocytes play a ..
  35. Cook D, Meade M, Guyatt G, Walter S, Heels Ansdell D, Warkentin T, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364:1305-14 pubmed publisher
    ..In this multicenter trial, we tested the superiority of dalteparin over unfractionated heparin by randomly assigning 3764 patients to receive either subcutaneous dalteparin (at a ..
  36. Li W, Yang X, Wang L, Ge Y, Wang H, Xu L, et al. Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients. Chin Med J (Engl). 2011;124:3275-80 pubmed
    ..aimed to determine the clinical outcomes of tirofiban combined with the low molecular weight heparin (LMWH), dalteparin, in primary PCI patients with acute STEMI...
  37. Altinbas M, Coskun H, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266-71 pubmed
    ..LMWH consisted of dalteparin given at a dose of 5000 U once daily during the 18 weeks of CT. Results Overall tumor response rates were 42...
  38. Schmid P, Brodmann D, Odermatt Y, Fischer A, Wuillemin W. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009;7:1629-32 pubmed publisher
    ..Evaluate pharmacokinetic data of dalteparin at a therapeutic dose in patients with RI. Prospective observational cohort study...
  39. Husted S, Wallentin L, Lagerqvist B, Kontny F, Stahle E, Swahn E. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J. 2002;23:1213-8 pubmed
    ..for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach...
  40. Perry J, Julian J, Laperriere N, Geerts W, Agnelli G, Rogers L, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8:1959-65 pubmed publisher
    ..We tested the efficacy of long-term dalteparin low-molecular-weight heparin (LMWH) for prevention of VTE in these patients...
  41. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7:58-64 pubmed publisher
    ..Our aim was to investigate the effectiveness of dalteparin, a low-molecular-weight heparin, in preventing the recurrence of these complications in women without ..
  42. Rodger M, Kahn S, Cranney A, Hodsman A, Kovacs M, Clement A, et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost. 2007;5:1600-6 pubmed
    ..We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD...
  43. Polkinghorne K, McMahon L, Becker G. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis. 2002;40:990-5 pubmed
    ..We performed a prospective randomized study of the pharmacokinetics of dalteparin and enoxaparin plus danaparoid in 21 hemodialysis patients...
  44. Hull J, Hull P. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer. N Engl J Med. 2003;349:1385-7; author reply 1385-7 pubmed
  45. Boström S, Hansson G, Kjaer M, Sarich T. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis. 2003;14:457-62 pubmed
    ..The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively...
  46. Bick R. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol. 2006;4:115-20 pubmed
    ..Anticoagulant Therapy for the Prevention of Recurrent VTE in Patients With Cancer), extended LMWH therapy with dalteparin represents an alternative to standard oral anticoagulation...
  47. Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica. 2006;91:207-14 pubmed
    ..The aim of this study was to compare the antithrombotic effects of a LMWH, i.e. dalteparin, with UFH on both microvascular (human microvascular endothelial cells [HMEC-1]) and macrovascular (human ..
  48. Tsukada S, Enomoto N, Takei Y, Hirose M, Ikejima K, Kitamura T, et al. Dalteparin sodium prevents liver injury due to lipopolysaccharide in rat through suppression of tumor necrosis factor-alpha production by Kupffer cells. Alcohol Clin Exp Res. 2003;27:7S-11S pubmed
    ..Recently, heparin has been reported to diminish TNF-alpha production from macrophages in response to LPS. Dalteparin sodium (DS) is a low-molecular-weight heparin with a mean molecular weight of 5,000...
  49. Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care. 2008;12:R32 pubmed publisher
    ..of critically ill patients with severe acute or chronic renal insufficiency or dialysis receiving subcutaneous dalteparin 5,000 IU once daily, we estimated the prevalence of proximal DVT by screening compression venous ultrasound of ..
  50. Handschin A, Trentz O, Hoerstrup S, Kock H, Wanner G, Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg. 2005;92:177-83 pubmed
    ..Primary human osteoblast cell cultures were incubated with either the low molecular weight heparin dalteparin at concentrations of 30, 300 and 900 microg/ml or with fondaparinux at concentrations of 25, 50, 100, 150, 200 ..
  51. Lapidus L, Rosfors S, Ponzer S, Levander C, Elvin A, Lärfars G, et al. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. J Orthop Trauma. 2007;21:52-7 pubmed
    ..The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture...
  52. Rasmussen M, Jorgensen L, Wille Jørgensen P, Nielsen J, Horn A, Mohn A, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384-90 pubmed
    ..To evaluate the efficacy and safety of thromboprophylaxis with the low molecular weight heparin (dalteparin), administered for 28 days after major abdominal surgery compared to 7 days' treatment...
  53. Tincani E, Mannucci C, Casolari B, Turrini F, Crowther M, Prisco D, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006;91:976-9 pubmed
    The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to ..